Clinical Trials - September 9, 2020
Calliditas enrolls first patient in China in Phase 3 study
Calliditas Therapeutics has announced that the first patient in China has been randomized into confirmatory part of the NefIgArd Phase 3 trial by its partner, Everest Medicines. Following IND approval by the NMPA in December of 2019 and subsequent approval by Human Genetic Resources Administration of China (HGRAC), the first patient in China has now […]
Pharma Business - May 18, 2020
Calliditas files registration statement for proposed IPO in the US
Calliditas Therapeutics has publicly filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its American Depositary Shares, representing Calliditas’ common shares, in the United States and a concurrent private placement of its common shares in Europe and other countries outside of the […]
Financing - December 19, 2019
Calliditas announces first milestone payment from Everest Medicines
Calliditas Therapeutics has announced that a $5 million milestone payment from its partner Everest Medicines II Limited has been triggered as per the licensing agreement under which Everest is to develop and commercialize Calliditas’ leading drug candidate Nefecon in Greater China and Singapore. The National Medical Products Administration (NMPA, formerly known as CFDA) has approved […]
